The Proglucagon Enzyme Linked Immunosorbent Assay (ELISA) kit provides materials for the quantitative measurement of Proglucagon in human plasma and other biological fluids. No detectable cross-reactivity to Glucagon, GLP-1, GLP-2, Oxyntomodulin, GRPP, MPGF-1, MPGF-2, Insulin, C-Peptide, or Thyroglobulin.
| Catalog Number | |
|---|---|
| Packaging | 96 well microtiter |
| Species Reactivity | Enquire about animal-specific cross-reactivity |
| Detection | HRP-based ELISA, colorimetric detection by dual wavelength absorbance at 450 nm and 630 nm as reference filter |
| Dynamic Range | 6, 6.48 – 913 pg/mL |
| Limit of Detection | 1.14 pg/mL |
| Sample Size | 25 µL |
| Sample Type | Plasma |
| Assay Time | 2.5 hours |
| Shelf Life | 24 months |
| Availability | Worldwide |
Proglucagon, a 158 amino acid polypeptide, is synthesized in the pancreatic alpha cells and the intestinal L-cells1. Its post-translational processing in the pancreas leads to GRPP, Glucagon, IP-1 and MPGF. While in the intestines, the post-translational process leads to Glicentin, Oxyntomodulin, GLP-1, IP-2 and GLP-2.2 Analogs and agonists of these proglucagon factors are used in the treatment and management of Type-1 and Type-2 diabetes and prevention of cardiovascular complications associated with diabetes.
References:
- Jacques Philippe, Svetlana Mojsov, Daniel J. Drucker, Joel F. Habener., Proglucagon Processing in a Rat Islet Cell Line Resembles Phenotype of Intestine Rather than Pancreas, Endocrinology, Volume 119, Issue 6, 1 December 1986, Pages 2833–2839.
- Raffort, J., Lareyre, F., Massalou, D., Fénichel, P., Panaïa-Ferrari, P., & Chinetti, G. (2017). Insights on glicentin, a promising peptide of the proglucagon family. Biochemia medica, 27(2), 308–324.
Proglucagon ELISA AL-1019
Stefanakis K, Kokkinos A, Argyrakopoulou G, et al. Circulating levels of proglucagon derived peptides are differentially regulated by the glucagon like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study. Diabetes Obes Metab. 023;25(9):2561‐2574. doi:10.1111/dom.15141
All Products Cited: C-Peptide of Insulin ELISA AL-151; Glicentin ELISA AL-185; GLP-1 ELISA AL-172; GLP-2 ELISA AL-174; Glucagon ELISA AL-157; Proglucagon ELISA AL-1019; MPGF ELISA AL-175; Oxyntomodulin AL-139